⚡⚡(HILO OFICIAL) : CRISIS DEL cobi19 ☣SARS-CoV2☣

[RagnarokCoronavirus2]

Mira..lo.mismo que va a pasar cuando empiezen las banderillas..así en todos los hospitales

Un brote afecta a 35 del hospital de Salt
La dirección del Hospital Santa Caterina de Salt ha confirmado este jueves la detección de un brote de cobi19 en una de las unidades de hospitalización del centro que ha afectado a 20 pacientes y a 15 trabajadores. Según un comunicado emitido esta tarde, han aislado la unidad afectada de manera que la planta se ha dividido en dos unidades destinadas con pacientes con el bichito y dos unidades a pacientes "no el bichito".

 

[rejon]

La prueba irrefutable de que en Madrid la situación sanitaria va bien es que de repente todas las críticas van contra la fiscalidad.

 

[Guanotopía]

Luisito, no es oro, y ya se esta haciendo, lo de Italia, pues sin mas, monetizar la deuda y mantenerla en balance ad Infinitum o cancelarla a efectos prácticos es lo mismo

La diferencia es que mientras reconozcas la deuda te desmontan el país a precio de saldo como le sucede a Grecia, y si haces un simpa, vives a la argentina.

 

[esteban_m]

OT

CAOS total en Buenos Aires en el funeral de Maradona.
No tuvieron mejor idea de dar por terminado todo dejando una multitud afuera.

 

[Guanotopía]

¿Os acordáis cuando se decía que las costumbres sobonas, fiesteras y el apretujismo español no tenían nada que ver con la expansión del bichito porque Italia, Portugal y Grecia no estaban igual?

Pues echando un vistazo a las cifras estos días, va a ser que sí tienen que ver.

 

[RagnarokCoronavirus2]

Parece que el Rumano DR sigue siendo negativo, aunque parece que ya no se moja tanto con datos concretos..

 

[I'm back]

Pues menos mal que Italia tenía bajo control la segunda ola.

 

[Caronte el barquero]

Con ese IMC estás para ganar el Tour.

ja.ja,ja siempre se puede mejorar , pero no es plan, que si un día sólo como hamburguesas, pizza, o patatas fritas no pasa nada , no soy un Talibán de nada.

Mucho ejercicio tampoco es bueno, pero es de los pocos vicios que tengo.

 

[Latune]

 

[Octubrista]

Ya se habrá dicho, pero la banderilla de "Oxford" que Sánchez tanto anuncia en su "Aló Presidente", parece que necesita de más "estudios" (tras unos errores chapuceros que trataron de pasar por alto):


Doubts raised over AstraZeneca-Oxford vaccine data
Oxford university acknowledges error that forced trial to switch dosing regimens

Surgen dudas sobre los datos de la banderilla AstraZeneca-Oxford
La universidad de Oxford reconoce el error que obligó al ensayo a cambiar los regímenes de dosificación

La noticia extensa (como piden subscripción, lo pongo para que se pueda leer) :
Subscribe to read | Financial Times

Disquiet is growing over the way that Oxford university and AstraZeneca have handled the early readout from trials of their cobi19 vaccine, which much of the developing world may rely on to emerge from the pandemic. The results were hailed a success for showing an average efficacy of 70 per cent — a figure reached by pooling the results from cohorts on two different dosing regimens. One set of participants received two identical doses a month apart, while the other group received a half-dose, and then a full dose. The efficacy for the first, larger group was 62 per cent. In the second subgroup, it was 90 per cent. It has emerged that administration of the half-dose started with a mistake. It was then given to a smaller number of participants than those who received two full doses, making the discovery of its greater effectiveness look like a lucky break. Yet on Tuesday, Moncef Slaoui, the head of Operation Warp Speed, the US government’s funding programme for vaccine development, disclosed that second subgroup was also limited to people aged 55 or below, a demographic with lower risk of developing severe el bichito-19. Oxford and AstraZeneca did not disclose the age breakdown on Monday, when results were released. “There are a number of variables that we need to understand,” Mr Slaoui said. It is still possible the difference in efficacy was “random”, he added. Markets have taken notice. London-listed shares in AstraZeneca have lost more than 6 per cent since the announcement. By comparison, since trial results from their vaccine were released earlier this month, showing an effectiveness of 90 per cent, shares in Pfizer and BioNTech have gained 6 per cent and 14 per cent respectively; Moderna is up 11 per cent since its vaccine trial data came out, on top of big gains in the run-up to publication.

One early critic this week, Geoffrey Porges, an analyst at SVB Leerink, said he thought it was unlikely the AstraZeneca jab would get approval in the US after the company “tried to embellish their results” by highlighting higher efficacy in a “relatively small subset of subjects in the study”. John LaMattina, a former president of Pfizer’s global research and development unit, said in a tweet it was “hard to believe” US regulators would issue an emergency-use authorisation for a “vaccine whose optimal dose has only been given to 2,300 people”. Much of the confusion stems from Oxford and AstraZeneca not being fully forthcoming on the reason for the two different dosing regimens — which changed unexpectedly as trials progressed. In a statement late on Wednesday, Oxford acknowledged a difference in manufacturing and measurement processes meant later phases of its clinical studies resulted in half a dose being mistakenly administered instead of a full one.

The Wednesday statement said this was discussed with regulators at the time, who agreed to use two testing regimens. “The methods for measuring the concentration are now established and we can ensure that all batches of vaccine are now equivalent,” it said. Richard Lawson, a UK trial participant who still does not know whether he was given the vaccine or a placebo because the trial has not yet been unblinded, told the Financial Times he was informed of the mix-up in July, before getting a booster shot. As a general rule, vaccinologists usually aim for the lowest dose that is still effective, but the efficacy of the lower dose is still not explained. Oxford professor Sarah Gilbert has said it is possible that a smaller initial dose primes the immune system in a way that better mimics natural infection. But there is no precedent for other vaccines to be administered in this way. “We just don’t have all the information we need to tell whether these results are reliable,” said Natalie Dean, an assistant professor of biostatistics at the University of Florida. “We certainly don’t have enough information in the public domain to decide whether this half dose is really working.”

Prof Dean contrasted the AstraZeneca disclosures with those from other trials. “We had this precedent set by the other vaccines with Moderna and Pfizer/BioNTech and these were single trials, with a protocol released in advance,” she said. “We had a chance to look through it . . . It was fairly straightforward.” There are also concerns at variations in the trial of the Oxford vaccine in different countries. As well as different dosing regimens, there were also differences between the control groups in different countries: in the UK, participants who did not get the el bichito-19 vaccine were administered a meningococcal vaccine; in Brazil they got a saline placebo. These discrepancies have led to the suggestion that the data is too patchy to combine into a single convincing efficacy result. An AstraZeneca spokesman defended the trial, saying they were “conducted to the highest standards” and met their primary efficacy endpoint. The company has said more data will continue to accumulate and additional analysis will be conducted, refining the efficacy reading and establishing how long the vaccine protects against the bichito. The results will appear in a peer-reviewed journal, and regulators have set an efficacy threshold of 50 per cent, meaning a jab with a 70 per cent efficacy would still get approved.

Despite the questions over efficacy, the Oxford/AstraZeneca vaccine does offer some undisputed advantages. It is cheaper than the mRNA vaccines from Moderna and Pfizer/BioNTech and can be stored in a refrigerator rather than a freezer. Oxford university said it “completely” understood the interest in the discovery of the dosing mistake and the switch in dosing tactics, which was approved by UK regulators. “As this is a complicated scientific area, our scientists would like to wait until the peer-reviewed publication of the interim phase 3 results in The Lancet [medical journal] before discussing this further, which we anticipate will be in the next few weeks,” it said.





Alguna cosilla más:

AstraZeneca Plans New Global Vaccine Study: Live Updates
AstraZeneca needs to collect more data on its vaccine after what it has released so far has elicited more questions than answers...

 

[IMeLk0RI]

Por todo lo que se ha leido hasta la fecha, a los pobres diablos a los que les habian metido el banderillazo, eran CONTAGIADORES y MUY MUY SINTOMATICOS. Vamos que la practica totalidad de quienes les habian pinchado decian que no se habian sentido tan enfermos en su fruta vida.

Que me llamen loco, pero mis cortas entendederas me dicen que una banderilla es algo que se pincha para evitar que te contagies de algo y que no te afecte. Con esto lo que estan haciendo es, basicamente, INOCULARTE LA ENFERMEDAD Y CONTAGIARTE, asi, sin mas. Eres contagiador y sufres los sintomas.

¿Entonces para que ostra fruta me quiero pinchar? Es como si lo que estuvieran buscando es UN ACELERADOR. Hacer que todo el puñetero mundo se contagie y enferme rapidito, y asi que todos los que se tengan que morir lo hagan rapidito ala vez en un mes, y todos los demas a remar como buenos esclavos

Porque a pesar de lo que diga el populismo virológico mediático, es un bichito del chichinabo. Lo lógico, normal e incluso deseable es que el bichito circule libremente y los infectados lo sean de forma natural. Punto. Y es lo que al menos yo llevo diciendo desde el principio, ni un ápice ha cambiado mi postura.

 

[davinci79]

el bichito-19 EN ASTURIAS
Actualización: 26 Noviembre 2020

- Hoy se reportan 259 nuevos positivos en 5677 pruebas realizadas (un 4.56%)
- Las hospitalizaciones en planta bajan de 770 a 712.
- La ocupación de camas UCI se mantiene en 144.
- Se reportan 23 fallecimientos: once mujeres de 71, 72, 82, 87, 90, 91, 91, 93, 94, 96 y 98 años, y doce varones de 49, 60, 60, 72, 80, 82, 85, 85, 87, 90, 91 y 95. Trece de estas personas tenían domicilio en un centro residencial de mayores.
- Realmente, se suman 25 fallecimientos.

Fallecidos 1ª ola: 340
Fallecidos 2ª ola: 591

 

[rejon]

— ¡Abran, policía!. Hay más de seis personas cenando en la vivienda.
— Somos ocupas.
— Ustedes perdonen. Feliz Navidad.

 

[Caronte el barquero]

Siguen muy altos de positividad + del 10%

 

[rejon]

- Qué vergüenza, el Ministerio de Sanidad aconseja máximo 6 personas en Navidad y Madrid dice que hasta 10 personas !!! Por fastidiar !!

-x- Navarra también permitirá hasta 10 personas.

- Ah, bueno, entonces 10 ya parece un límite adecuado y lógico, con base científica...